Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177-Lu-DOTA-cG250 in advanced renal cancer
NCT00142415Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Feb 2005
- Primary completion
- Jan 2011
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of 177-Lu-DOTA-cG250 in clear cell renal cell carcinoma (ccRCC), sponsored by Ludwig Cancer Research. Started Feb 2005; status: completed.
02
Drugs
177-Lu-DOTA-cG250
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00142415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142415.